FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/05/2026
Voltar para busca
Dado oficial do USPTO
AXCYNSIS AXCYNSIS THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
22/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
23/07/2024
Data de registro
21/10/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/10/2025
Última transação
22/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
24
Localização do titular
SG
Examinador
DIEFENBACH, LINDSEY OLSON
Unidade examinadora
O90
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "AXCYNSIS" in which the lettering "AXC" is formed by a blue geometric figure with connecting diagonal and horizontal lines resembling a molecular model, the letter "Y" appears in teal and is angled to one side and surrounded by two teal diagonal lines also resembling an Antibody, and the lettering "NSIS" appears in teal stylized font. All of the foregoing appears above the stylized black wording "AXCYNSIS THERAPEUTICS". The color white represents background and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
AXCYNSIS THERAPEUTICS PTE. LTD.
Representantes
Joseph G. Chu JCIP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical productspharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposesfor oncology.
Classe 42
Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharmaceutical studies; consultancy relating to pharmaceutical research and development; consultancy relating to pharmaceutical research and development in the field of therapeutics; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; DNA sequencing being DNA analysis for medical research purposes; DNA sequencing technology research; gene therapy research; scientific research in the field of genetics and antibody drug conjugates; genetic testing for scientific research purposes; laboratory research in the fields of antibody drug conjugates in oncology and antibody drug conjugate development; laboratory research in the field of chemistry; laboratory research in the field of gene expression; laboratory research in the field of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical research; medical research in the field of oncology; medical research laboratory services; medical research services; pharmaceutical research and development services; pharmaceutical research consultancy; pharmaceutical research services; chemical research services in the nature of preparation of scientific reports relating to chemical research; scientific research services in the nature of preparation of scientific reports relating to scientific research; product research; product research and development; providing information about medical and scientific research in the field of pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; providing information and online information about scientific and technological services in the field of antibody drug conjugates in oncology and research and design relating thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of information relating to scientific research; provision of information relating to technological research in the field of antibody drug conjugates in oncology; research servicesscientific research; research and development in the field of biotechnology; research and development of new products; research and development of new products for others; research and development services for the pharmaceutical industry; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of biochemistry; research and development services in the field of biotechnology; research and development services in the field of chemistry; research and development services in the field of pharmaceutical preparations; research in the field of biology; research in the field of biomedicine; research in the field of biotechnology; research in the field of chemistry; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to chemistry; research relating to chemicals; research relating to medicine in the nature of medical research; research relating to molecular sciences; research relating to pharmaceuticals; research relating to science; research laboratory analysis services in the field of chemistry and bioconjugation; research to develop new products; scientific and industrial research in the field of antibody drug conjugates in oncology; scientific and technological servicesresearch and design in the field of antibody drug conjugates in oncology; scientific and technological servicesresearch and development in the field of antibody drug conjugates in oncology; scientific research; scientific research and analysis for scientific research purposes; scientific research and development; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of biotechnology; scientific research into the development of new products; scientific research relating to biology; scientific research relating to chemistry; scientific research relating to chemical products; scientific research relating to genetics; scientific research services; technical research in the field of pharmaceutical studies; technical research projects and studies in the field of antibody drug conjugates in oncology.
Classe 44
Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testinginspectionresearch of pharmaceuticals.
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
30/04/2026
FIMP
FINAL DISPOSITION PROCESSED
30/04/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
09/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/03/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
23/03/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/01/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/10/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
21/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/09/2025
PUBO
PUBLISHED FOR OPPOSITION
02/09/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/07/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
28/07/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/07/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
28/07/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/07/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/07/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/07/2025
RFNT
REFUSAL PROCESSED BY IB
22/03/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/03/2025
RFRR
REFUSAL PROCESSED BY MPU
04/03/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/01/2025
CNRT
NON-FINAL ACTION WRITTEN
15/01/2025
DOCK
ASSIGNED TO EXAMINER
10/01/2025
MAFR
APPLICATION FILING RECEIPT MAILED
08/11/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/11/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/10/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AXCYNSIS AXCYNSIS THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.